ENDRA Life Sciences Inc Registered Shs NDRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NDRA is a good fit for your portfolio.
News
-
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
-
ENDRA Life Sciences Installs First TAEUS System in the UK
-
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System
-
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
Trading Information
- Previous Close Price
- $0.25
- Day Range
- $0.25–0.26
- 52-Week Range
- $0.22–2.79
- Bid/Ask
- $0.25 / $0.26
- Market Cap
- $2.87 Mil
- Volume/Avg
- 42,059 / 186,183
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.endrainc.com
Valuation
|
Metric
|
NDRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.48 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NDRA
|
|---|---|
Quick Ratio | 3.14 |
Current Ratio | 3.36 |
Interest Coverage | — |
Quick Ratio
NDRA
Profitability
|
Metric
|
NDRA
|
|---|---|
Return on Assets (Normalized) | −114.33% |
Return on Equity (Normalized) | −153.26% |
Return on Invested Capital (Normalized) | −141.91% |
Return on Assets
NDRA
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Vtwhsdbxbj | Gnqsq | $209.3 Bil | |
DHR
| Danaher Corp | Qnpczvmjfc | Scqpvk | $185.5 Bil | |
IQV
| IQVIA Holdings Inc | Tvnsnlxf | Qythr | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Xsnvsmdb | Dpynfb | $41.0 Bil | |
A
| Agilent Technologies Inc | Pblylyzy | Kfc | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Rnxntpdyv | Lrtysp | $26.4 Bil | |
ICLR
| Icon PLC | Vdcmgyzdt | Znrfh | $25.2 Bil | |
ILMN
| Illumina Inc | Fjngfpfc | Lqgnfl | $19.6 Bil | |
WAT
| Waters Corp | Fkktlvxw | Gth | $18.0 Bil | |
LH
| Laboratory Corp of America Holdings | Pvqtylld | Xmbzznk | $17.5 Bil |